NBI-74330
NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of (125I) CXCL10 and (125I) CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively.
Product Specifications
CAS Number
855527-92-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology
Assay Protocol
https://www.medchemexpress.com/NBI-74330.html
Purity
99.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N([C@@H](C1=NC2=NC=CC=C2C(N1C3=CC=C(OCC)C=C3)=O)C)CC4=CC=CN=C4)CC5=CC=C(F)C(C(F)(F)F)=C5
Molecular Formula
C32H27F4N5O3
Molecular Weight
605.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Heise CE, et al. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313 (3) :1263-71.|[2]Jopling LA, et al. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br J Pharmacol. 2007 Dec;152 (8) :1260-71.|[3]van Wanrooij EJ, et al. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008 Feb;28 (2) :251-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CXCR3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY400883 100 µg
Myosin Phosphatase (PPP1R12A) (NM_002480) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC682603-500 1x 500 µL
Calretinin / Calbindin 2 (Mesothelioma Marker) (CALB2/2603), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 